RECORDATI
Recordati S.p.A., a prominent player in the pharmaceutical industry, is headquartered in Luxembourg (LU) and operates extensively across Europe, North America, and other global markets. Founded in 1926, Recordati has established itself as a leader in the development and marketing of innovative medicines, particularly in the fields of rare diseases and specialty pharmaceuticals. The company’s core offerings include a diverse range of prescription drugs, with a strong emphasis on treatments for rare diseases, urology, and cardiovascular conditions. Recordati's commitment to research and development sets it apart, enabling the introduction of unique therapies that address unmet medical needs. With a robust market position, Recordati has achieved significant milestones, including strategic acquisitions and partnerships that enhance its portfolio and global reach.
DitchCarbon Score
How does RECORDATI's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
RECORDATI's score of 36 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
RECORDATI's reported carbon emissions
In 2023, RECORDATI reported total carbon emissions of approximately 36,607,000 kg CO2e from Scope 1 and 2 sources. This includes about 8,223,000 kg CO2e from mobile combustion and 200,000 kg CO2e from fugitive emissions. The company also recorded Scope 2 emissions of approximately 15,660,000 kg CO2e, with a total of about 38,173,000 kg CO2e when combining both scopes. Over the years, RECORDATI has demonstrated a commitment to reducing its carbon footprint. The company has set a target to reduce its Scope 1 and Scope 2 greenhouse gas emissions by 42% by 2030, using 2023 as the base year. This target aligns with the science-based criteria necessary to limit global warming to 1.5°C, reflecting a proactive approach to climate action. In previous years, RECORDATI's emissions have shown fluctuations, with Scope 1 emissions peaking at approximately 37,768,000 kg CO2e in 2022 and Scope 2 emissions reaching about 10,002,000 kg CO2e in the same year. The company has not disclosed any Scope 3 emissions data, indicating a potential area for future focus. Overall, RECORDATI's climate commitments and reduction targets underscore its dedication to sustainability and responsible environmental stewardship, positioning the company as a forward-thinking entity in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 34,458,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 10,567,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
RECORDATI is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
